Molecular Therapy — Nucleic Acids · 2017 · 140 citations · 33 references
Life SciencesGeneticsNeurologyGene DeliveryMolecular NeuroscienceNeurodegenerationMolecular Basis Of NeurodegenerationMolecular NeurogeneticsNeurodegenerative DiseasesNeurodegenerative DisordersNeurogenetic DisordersOligonucleotide DeliveryBrain RegionsKnockout Mouse ModelsNeurodegenerative CascadePolyglutamine DiseasesPolyglutamine Expansion DisordersRepeat Expansion MutationsSpinocerebellar Ataxia ModelsSpinocerebellar Ataxia Type 3
The most common dominantly inherited ataxia, spinocerebellar ataxia type 3 (SCA3), is an incurable neurodegenerative disorder caused by a CAG repeat expansion in the ATXN3 gene that encodes an abnormally long polyglutamine tract in the disease protein, ATXN3. Mice lacking ATXN3 are phenotypically normal; hence, disease gene suppression offers a compelling approach to slow the neurodegenerative cascade in SCA3. Here we tested antisense oligonucleotides (ASOs) that target human ATXN3 in two complementary mouse models of SCA3: yeast artificial chromosome (YAC) MJD-Q84.2 (Q84) mice expressing the full-length human ATXN3 gene and cytomegalovirus (CMV) MJD-Q135 (Q135) mice expressing a human ATXN3 cDNA. Intracerebroventricular injection of ASOs resulted in widespread delivery to the most vulnerable brain regions in SCA3. In treated Q84 mice, three of five tested ASOs reduced disease protein levels by >50% in the diencephalon, cerebellum, and cervical spinal cord. Two ASOs also significantly reduced mutant ATXN3 in the mouse forebrain and resulted in no signs of astrogliosis or microgliosis. In Q135 mice expressing a single ATXN3 isoform via a cDNA transgene, ASOs did not result in similar robust ATXN3 silencing. Our results indicate that ASOs targeting full-length human ATXN3 would likely be well tolerated and could lead to a preventative therapy for SCA3.
33
Timothy M. Miller, Alan Pestronk, William David et al. · The Lancet Neurology · 2013 · 607 citations · Full text
Medicine, Neurology, Pharmacology +17
Clotilde Lagier‐Tourenne, Michael W. Baughn, Frank Rigo et al. · Proceedings of the National Academy of Sciences · 2013 · 557 citations · Full text